

TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

**ANNOUNCEMENT ON KEY OPERATING DATA OF THE COMPANY FOR THE PERIOD FROM
JANUARY TO FEBRUARY 2022**

The board of directors (the "Board") and every individual director of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the "Company") hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

1. Key operating data from January to February 2022

Based on preliminary estimates, from January to February 2022, the Company achieved an operating income of approximately RMB1,300 million, representing a year-on-year increase of approximately 5%, and the net profit attributable to shareholders of the Company was approximately RMB150 million, representing a year-on-year increase of approximately 21% (the "Estimated Operating Data").

2. Other matters

- (a) The Estimated Operating Data is preliminary accounting data and is provided as periodic financial data for shareholders and investors' reference only and cannot be used to project the Company's annual results.
- (b) The media platforms designated by the Company for information disclosure are the China Securities Journal (中国证券报), Shanghai Securities Journal (上海证券报), the website of the Shanghai Stock Exchange (www.sse.com.cn) and the website of the Singapore Exchange Securities Trading Limited (www.sgx.com). All information disclosed by the Company shall be subject to the official announcement(s) published on the aforesaid designated media platforms which shall prevail.

Shareholders of the Company and potential investors are advised to make investments in a rational manner and be aware of the risks involved.

BY ORDER OF THE BOARD

Jiao Yan
Secretary to the Board of Directors

30 March 2022